• Consensus Rating: Buy
  • Consensus Price Target: $5.87
  • Forecasted Upside: 49.28%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.93
▲ +0.08 (2.08%)

This chart shows the closing price for CDXC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ChromaDex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXC

Analyst Price Target is $5.87
▲ +49.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ChromaDex in the last 3 months. The average price target is $5.87, with a high forecast of $6.60 and a low forecast of $5.00. The average price target represents a 49.28% upside from the last price of $3.93.

This chart shows the closing price for CDXC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in ChromaDex. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Roth MkmBoost TargetBuy ➝ Buy$4.25 ➝ $6.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00N/A
5/11/2023LADENBURG THALM/SH SHLower Target$7.50 ➝ $6.60Low
3/13/2023HC WainwrightLower TargetBuy$5.50 ➝ $5.00Low
2/1/2023HC WainwrightReiterated RatingBuy$5.50Low
11/3/2022B. RileyLower Target$2.40 ➝ $2.10Low
8/29/2022HC WainwrightLower TargetBuy$7.00 ➝ $5.50Low
8/16/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
8/11/2022B. RileyDowngradeBuy ➝ Neutral$6.00 ➝ $2.40Low
6/7/2022HC WainwrightLower TargetBuy$8.00 ➝ $7.00High
5/17/2022OppenheimerLower TargetNA$7.00Medium
5/13/2022B. RileyLower Target$8.00 ➝ $6.00Low
4/18/2022HC WainwrightLower TargetBuy$12.00 ➝ $8.00High
3/10/2022B. RileyLower TargetBuy$16.00 ➝ $8.00High
3/8/2022Roth CapitalInitiated CoverageBuy$7.00Low
10/8/2021HC WainwrightReiterated RatingBuy$12.00Low
9/17/2021HC WainwrightReiterated RatingBuy$12.00Medium
8/4/2021HC WainwrightBoost TargetBuy$11.00 ➝ $12.00High
5/17/2021HC WainwrightLower TargetBuy$16.00 ➝ $11.00High
5/10/2021HC WainwrightLower TargetBuy$11.00High
3/16/2021HC WainwrightBoost TargetBuy$7.00 ➝ $16.00High
3/10/2021OppenheimerInitiated CoverageBuy$9.00High
3/8/2021B. RileyBoost TargetBuy$7.00 ➝ $18.00High
12/2/2020OppenheimerReiterated RatingBuy$9.00High
11/5/2020OppenheimerReiterated RatingBuy$9.00High
10/12/2020HC WainwrightReiterated RatingBuy$7.00Low
10/6/2020OppenheimerBoost TargetOutperform$6.00 ➝ $9.00High
8/18/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $7.00High
8/7/2020OppenheimerReiterated RatingBuy$6.00High
7/14/2020B. RileyReiterated RatingBuy$7.00Medium
5/13/2020OppenheimerInitiated CoverageBuy$6.00High
5/12/2020HC WainwrightReiterated RatingBuy$6.00High
4/21/2020OppenheimerReiterated RatingBuy$6.00Medium
3/9/2020B. RileyReiterated RatingBuyHigh
2/27/2020HC WainwrightReiterated RatingBuy$6.00Medium
1/21/2020HC WainwrightReiterated RatingBuy$6.00Low
10/15/2019OppenheimerInitiated CoverageOutperform$6.00High
5/28/2019HC WainwrightSet TargetBuy$7.00High
4/25/2019HC WainwrightReiterated RatingBuy$7.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2023
  • 8 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/18/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/16/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
ChromaDex logo
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $3.93
Low: $3.75
High: $3.97

50 Day Range

MA: $2.52
Low: $1.52
High: $4.32

52 Week Range

Now: $3.93
Low: $1.25
High: $4.65

Volume

232,891 shs

Average Volume

253,783 shs

Market Capitalization

$295.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of ChromaDex?

The following Wall Street sell-side analysts have issued reports on ChromaDex in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, Roth Mkm, and StockNews.com.
View the latest analyst ratings for CDXC.

What is the current price target for ChromaDex?

3 Wall Street analysts have set twelve-month price targets for ChromaDex in the last year. Their average twelve-month price target is $5.87, suggesting a possible upside of 49.3%. LADENBURG THALM/SH SH has the highest price target set, predicting CDXC will reach $6.60 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for ChromaDex in the next year.
View the latest price targets for CDXC.

What is the current consensus analyst rating for ChromaDex?

ChromaDex currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDXC will outperform the market and that investors should add to their positions of ChromaDex.
View the latest ratings for CDXC.

What other companies compete with ChromaDex?

How do I contact ChromaDex's investor relations team?

ChromaDex's physical mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company's listed phone number is (310) 388-6706 and its investor relations email address is [email protected]. The official website for ChromaDex is www.chromadex.com. Learn More about contacing ChromaDex investor relations.